Tianjin SinoBiotech Ltd. & Beijing Bio-Fortune Ltd. Announce a U.S. Market Licensing Agreement for Their Intellectual Property on the Treatment of Neutropenia With One of the Global Top 10 Pharmaceutical Companies

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BEIJING--(BUSINESS WIRE)--Prof. Zailin Yu, Yan Fu with Tianjin SinoBiotech Ltd. & Beijing Bio-Fortune Ltd. (the “Licensor”), privately held biotechnology and biopharmaceutical companies, announced today that they have entered into a US market patent license agreement with one of the global top 10 pharmaceutical companies (the “Licensee”) on their intellectual property of the novel recombinant human serum albumin fusion protein drug for treatment of human neutropenia.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC